Form 4: uniQure Director Jack Kaye Receives Significant Equity Compensation

uniQure N.V. Director Jack Kaye was granted 7,970 restricted share units and 15,630 stock options as part of his compensation, aligning his interests with the company's performance.

Summary

• Jack Kaye, a Director of uniQure N.V. (QURE), reported the acquisition of equity securities.
• On June 11, 2025, Mr. Kaye was granted 7,970 Ordinary Shares in the form of Restricted Share Units (RSUs) under the Issuer's 2014 Share Incentive Plan.
• Each RSU represents the contingent right to receive one Ordinary Share, with a reported acquisition price of $0.
• These RSUs are scheduled to vest 100% on the first anniversary of the grant date, subject to Mr. Kaye's continued relationship with uniQure.
• Additionally, on June 11, 2025, Mr. Kaye was granted 15,630 Stock Options with an exercise price of $16.22 per share.
• These Stock Options also vest 100% on the first anniversary of the grant date, contingent on his continued relationship with the Issuer.
• The Stock Options have an expiration date of June 11, 2035.
• Following these transactions, Mr. Kaye beneficially owns 22,551 Ordinary Shares directly and 15,630 Stock Options directly.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive sign of alignment between management and shareholder interests, though it does not directly reflect operational or financial performance of the company.

Positives

• The grant of restricted share units and stock options to a director aligns their financial interests with the long-term performance and shareholder value of uniQure N.V.
• Equity compensation is a standard practice that incentivizes directors to contribute to the company's success.

Future Outlook

The document indicates that the granted restricted share units and stock options will vest 100% on the first anniversary of the grant date (June 11, 2026), contingent on the director's continued relationship with uniQure N.V. The stock options have an expiration date of June 11, 2035.

Industry Context

The grant of equity compensation, such as restricted share units and stock options, to directors is a common and expected practice across the biotechnology and pharmaceutical industries. It serves to align the interests of the board members with those of the shareholders, incentivizing long-term value creation.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with a one-year cliff vesting, is a standard practice for director compensation in the biotech sector.
• While specific compensation amounts vary by company size, performance, and individual roles, the use of equity to incentivize long-term commitment is consistent with global benchmarks for corporate governance and executive remuneration.

Corporate Governance

Related Party Transactions

• The grant of equity awards to a director constitutes a related party transaction, which is disclosed as part of standard compensation practices.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The restricted share units and stock options are expected to vest on June 11, 2026, subject to the director's continued relationship with uniQure N.V.

Key Dates

Keywords

uniQure, QURE, SEC Form 4, insider transaction, equity compensation, restricted share units, stock options, director compensation, beneficial ownership